103 related articles for article (PubMed ID: 25101761)
1. Pneumococcal conjugate vaccine administration during therapy for pediatric leukemia.
Crawford NW; Balloch A; Tikkanen L; Merchinaud F; Downie P; Buttery JP
Pediatr Infect Dis J; 2015 Jan; 34(1):e9-15. PubMed ID: 25101761
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
Hamaluba M; Kandasamy R; Upreti SR; Subedi GR; Shrestha S; Bhattarai S; Gurung M; Pradhan R; Voysey M; Gurung S; Pradhan S; Thapa AK; Maharjan R; Kiran U; Kerridge SA; Hinds J; van der Klis F; Snape MD; Murdoch DR; Kelly S; Kelly DF; Adhikari N; Thorson S; Pollard AJ
Lancet Infect Dis; 2015 Apr; 15(4):405-14. PubMed ID: 25701560
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
4. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
Thisyakorn U; Chokephaibulkit K; Kosalaraksa P; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S
Hum Vaccin Immunother; 2014; 10(7):1859-65. PubMed ID: 25424793
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
[TBL] [Abstract][Full Text] [Related]
12. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Klein NP; Ensor K; Jouve S; Northington R; Moscariello M; McGovern PC
Pediatr Infect Dis J; 2013 Sep; 32(9):990-7. PubMed ID: 24008739
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
17. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
[TBL] [Abstract][Full Text] [Related]
20. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.
Nived P; Nagel J; Saxne T; Geborek P; Jönsson G; Skattum L; Kapetanovic MC
Vaccine; 2017 Jun; 35(29):3639-3646. PubMed ID: 28552512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
